dc.contributor.author | Kent, S | en_US |
dc.contributor.author | Haynes, R | en_US |
dc.contributor.author | Hopewell, JC | en_US |
dc.contributor.author | Parish, S | en_US |
dc.contributor.author | Gray, A | en_US |
dc.contributor.author | Landray, MJ | en_US |
dc.contributor.author | Collins, R | en_US |
dc.contributor.author | Armitage, J | en_US |
dc.contributor.author | Mihaylova, B | en_US |
dc.contributor.author | Grp, H-TC | en_US |
dc.date.accessioned | 2018-11-16T10:16:39Z | |
dc.date.available | 2016-04-20 | en_US |
dc.date.issued | 2016-07 | en_US |
dc.date.submitted | 2018-05-31T11:34:14.173Z | |
dc.identifier.issn | 1941-7705 | en_US |
dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/51205 | |
dc.description.sponsorship | HPS2-THRIVE was supported by grants from Merck (manufacturer
of ER niacin–laropiprant, simvastatin, and ezetimibe), the UK
Medical Research Council (A310), the British Heart Foundation
(CH/1996001/9454), and Cancer Research UK (C500/A16896) (to
the University of Oxford), and by a fellowship from the British Heart
Foundation (FS/14/55/30806, to Dr Hopewell) | en_US |
dc.format.extent | 348 - + | en_US |
dc.relation.ispartof | CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES | en_US |
dc.subject | cardiovascular disease | en_US |
dc.subject | clinical trial | en_US |
dc.subject | hospital costs | en_US |
dc.subject | niacin | en_US |
dc.subject | quality of life | en_US |
dc.title | Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs | en_US |
dc.type | Article | |
dc.rights.holder | © 2016 American Heart Association, Inc. | |
dc.identifier.doi | 10.1161/CIRCOUTCOMES.115.002592 | en_US |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000380609700003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.issue | 4 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 9 | en_US |